The production base covers an area of about 13,000 m², with a total construction area of about 12,700 m² and an investment of hundreds of millions of RMB. It meets China’s cGMP requirements and is equipped with an automated hepatitis E vaccine production line and corresponding supporting facilities such as purified water, water for injection and other preparation works, sewage treatment, SPF-grade animal rooms and other works.

The bivalent HPV vaccine plant, with an investment of RMB 500 million, was put into use in 2017 and has workshops that meet GMP standards, with production processes complying with the latest GMP standards and the quality control management strictly following WHO-PQ requirements. The plant is equipped with the necessary equipment for production and quality inspection such as automatic vial filling line, automatic syringe filling line, fermentation system, liquid dispensing system and other process equipment, totaling more than 600 units (sets).

The production base, with a floor area of about 27,500 m², is a new intelligent GMP plant built according to world-class standards, and has established a quality management system that meets the regulations of China, FDA and EU. With a designed capacity of 200 million doses/year, the production workshop is equipped with imported disposable bioreactors, chromatographic purification systems, automatic filling lines and other equipment, a QC laboratory, an animal testing center, a cold storage and other supporting facilities.

The production base, with a floor area of about 60,000 m², is a new intelligent GMP plant built according to world-class standards, and has established a quality management system that meets the regulations of China, FDA and EU. With a designed capacity of 170 million doses/year, the production workshop is equipped with automatic large-scale filling lines, packaging lines, liquid dispensing systems and other equipment, a QC laboratory, a water production center, a cold storage and other supporting facilities.